Literature DB >> 20364416

Blood coagulation disorders in septic patients.

Paul Knoebl1.   

Abstract

Host defense and blood coagulation are tightly connected and interacting systems, necessary for the integrity of an organism. Complex mechanisms regulate the intensity of a host response to invading pathogens or other potentially dangerous situations. Under regular conditions, this response is limited in time and located to the site of injury. Sometimes, however, systemic host response is overwhelming and disproportional and causes damage, not cure. Dependent on the genetical predisposition of the host, its current immunocompetence, or the type of injury, the reaction leads to the clinical picture of the different degrees of sepsis. Septic organ dysfunction is caused by intravascular fibrin deposition as a result of coagulation activation, anticoagulant breakdown, and shut down of fibrinolysis. This article describes the major pathophysiologic reactions in these situations and presents www.SepDIC.eu, an online tool on sepsis and associated coagulopathy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20364416     DOI: 10.1007/s10354-009-0738-9

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  30 in total

1.  An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia.

Authors:  B White; W Livingstone; C Murphy; A Hodgson; M Rafferty; O P Smith
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

Review 2.  A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis.

Authors:  Christian J Wiedermann; Nicole C Kaneider
Journal:  Blood Coagul Fibrinolysis       Date:  2006-10       Impact factor: 1.276

Review 3.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

Review 4.  Regulation of inflammatory responses by natural anticoagulants.

Authors:  K Okajima
Journal:  Immunol Rev       Date:  2001-12       Impact factor: 12.988

5.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Authors:  B L Warren; A Eid; P Singer; S S Pillay; P Carl; I Novak; P Chalupa; A Atherstone; I Pénzes; A Kübler; S Knaub; H O Keinecke; H Heinrichs; F Schindel; M Juers; R C Bone; S M Opal
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

6.  Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.

Authors:  J Kienast; M Juers; C J Wiedermann; J N Hoffmann; H Ostermann; R Strauss; H-O Keinecke; B L Warren; S M Opal
Journal:  J Thromb Haemost       Date:  2006-01       Impact factor: 5.824

7.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

8.  Severe protein C deficiency predicts early death in severe sepsis.

Authors:  William L Macias; David R Nelson
Journal:  Crit Care Med       Date:  2004-05       Impact factor: 7.598

Review 9.  Activated protein C in sepsis: the promise of nonanticoagulant activated protein C.

Authors:  Hartmut Weiler; Wolfram Ruf
Journal:  Curr Opin Hematol       Date:  2008-09       Impact factor: 3.284

Review 10.  Inflammation, endothelium, and coagulation in sepsis.

Authors:  Marcel Schouten; Willem Joost Wiersinga; Marcel Levi; Tom van der Poll
Journal:  J Leukoc Biol       Date:  2007-11-21       Impact factor: 4.962

View more
  7 in total

1.  Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus.

Authors:  Hideki Ebihara; Barry Rockx; Andrea Marzi; Friederike Feldmann; Elaine Haddock; Douglas Brining; Rachel A LaCasse; Don Gardner; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

2.  Editorial: sepsis.

Authors:  Sylvia Knapp; Michael Frass
Journal:  Wien Med Wochenschr       Date:  2010-03

Review 3.  Novel aspects of fibrin(ogen) fragments during inflammation.

Authors:  Carla Jennewein; Nguyen Tran; Patrick Paulus; Peter Ellinghaus; Johannes Andreas Eble; Kai Zacharowski
Journal:  Mol Med       Date:  2011-01-04       Impact factor: 6.354

Review 4.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

5.  A Syrian golden hamster model recapitulating ebola hemorrhagic fever.

Authors:  Hideki Ebihara; Marko Zivcec; Donald Gardner; Darryl Falzarano; Rachel LaCasse; Rebecca Rosenke; Dan Long; Elaine Haddock; Elizabeth Fischer; Yoshihiro Kawaoka; Heinz Feldmann
Journal:  J Infect Dis       Date:  2012-10-08       Impact factor: 5.226

6.  Novel biomarkers for early prediction of sepsis-induced disseminated intravascular coagulation in a mouse cecal ligation and puncture model.

Authors:  Jingchun Song; Dunzhong Hu; Chao He; Tao Wang; Xuefeng Liu; Linhao Ma; Zhaofen Lin; Zili Chen
Journal:  J Inflamm (Lond)       Date:  2013-03-05       Impact factor: 4.981

7.  Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of randomized controlled trials.

Authors:  Yu Fan; Menglin Jiang; Dandan Gong; Chen Zou
Journal:  Sci Rep       Date:  2016-05-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.